Physician profile
Robert A Althar
NPI 1487655155
$231,388.28
in general payments reported to CMS, 2019-2025
8 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $34K · 2021: $34K · 2022: $32K · 2023: $35K · 2024: $35K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $100K · Food and Beverage: $76.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $99,600.00 |
| Food and Beverage | $76.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $131,375.00 | 2019-2022 | |
| Csl Plasma INC. | $99,600.00 | 2023-2025 | |
| Alkermes, INC. | $148.38 | 2019-2023 | Vivitrol |
| Neurocrine Biosciences, INC. | $71.91 | 2019-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $65.02 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $54.75 | 2022-2023 | Invega Trinza, Invega Sustenna |
| Indivior INC. | $40.52 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Althar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.